Vector Bioscience

Vector Bioscience is a University of Cambridge spin-out developing a machine learning-enabled drug delivery platform based on metal-organic framework nanoparticles.

The technology provides cargo-agnostic, targeted delivery of oligonucleotides and small molecules with controlled release, initially focused on hard-to-treat cancers.

The company has demonstrated in vivo proof-of-concept and is advancing GMP-aligned manufacturing processes, with over £3m raised in non-dilutive funding.